|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease显示文摘AIM: To evaluate the safety and feasibility of bone marrow cell (BMC) transplantation in patients with chronic liver disease on the waiting list for liver transplantation. METHODS: Ten patients (eight males) with chronic liver disease were enrolled to receive infusion of autologous bone marrow-derived cells. Seven patients were classified as Child-Pugh B and three as Child-Pugh C. Baseline assessment included complete clinical and laboratory evaluation and abdominal MRI. Approximately 50 ml of bone marrow aspirate was prepared by centrifugation in a ficoll-hypaque gradient. At least of 100 millions of mononuclear-enriched BMCs were infused into the hepatic artery using the routine technique for arterial chemoembolization for liver tumors. Patients were followed up for adverse events up to 4 mo. RESULTS: The median age of the patients was 52 years (range 24-70 years). All patients were discharged 48 h after BMC infusion. Two patients complained ofmild pain at the bone marrow needle puncture site. No other complications or specific side effects related to the procedure were observed. Bilirubin levels were lower at 1 (2.19 ± 0.9) and 4 mo (2.10 ± 1.0) after cell transplantation that baseline levels (2.78 ± 1.2). Albumin levels 4 mo after BMC infusion (3.73 ± 0.5) were higher than baseline levels (3.47 ± 0.5). International normalized ratio (INR) decreased from 1.48 (SD = 0.23) to 1.43 (SD = 0.23) one month after cell transplantation. CONCLUSION: BMC infusion into hepatic artery of patients with advanced chronic liver disease is safe and feasible. In addition, a decrease in mean serum bilirubin and INR levels and an increase in albumin levels are observed. Our data warrant further studies in order to evaluate the effect of BMC transplantation in patients with advanced chronic liver disease. | Andre Castro lyra Milena Botelho Pereira Soares luiz Flavio Maia da Silva Marcos Fraga Fortes André Goyanna Pinheiro Silva Augusto César de Andrade Mota Sheilla A Oliveira Eduardo lorens Braga Wilson Andrade de Carvalho Bernd Genser Ricardo Ribeiro dos Santos luiz Guilherme Costa lyra | 2007 | World Journal of Gastroenterology2007，13，7： | 21 |
| 2 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 3 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 4 | Detrimental effects of tropisetron on permanent ischemie stroke in the rat 显示文摘 | Eduardo C J Eduardo M Bernd L F | 2008 | BMC Neuroscience2008，9，6： | 1 |
| 5 | Expression and distribution of transcription factor NF-kB and inhibitor IkB in the in flamed peripheral nervous system显示文摘 | Bettina Andorfer Bernd C Kieseier Emily Mathey | 2001 | Journal of Neuroimmunology2001，116，： | 1 |
| 6 | No evidence of increased oxida- tive degradation of urate to allantoin in the CSF and serum of pa- tients with multiple sclerosis显示文摘 | Stefan K Bernd C Bernhard F | 2005 | J Neurol2005，252，5： | 1 |
| 7 | In vitro and in vivo studies on blends of isotactic and atactic poly (3-hydroxybutyrate) for development of a dura substitute material显示文摘 | Kunze C Edgar Bernd H Androsch R Nischan C Freier T Kramer S | 2006 | Biomaterials2006，27，： | 1 |
| 8 | Biomass for heat or as transportatioo fuel? A comparison between two modelbased studies 显示文摘 | GRAHN M AZAR C LINDGREN K BERNDES G GIELEN D | 2007 | Biomass Bioenergy2007，31，1112： | 1 |
| 9 | The feasibility of largescale lignocellulose-based bioenergy production 显示文摘 | Berndes G Azar C Kaberger T | 2001 | Biomass Bioenerg2001，20，： | 1 |
| 10 | Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma-analyses of cases from two prospective randomized clinical trials显示文摘 | Bernd HW Ziepert M Thorns C | 2009 | Haematologica2009，94，11： | 1 |
| 11 | Evolution of organic matter and nitrogen during co-composting of olive mill wastewater with solid organic wastes显示文摘 | Paredes C Roig A Bernd M P | 2000 | Biol Fertil Soils2000，32，： | 1 |
| 12 | The use of a Monte Carlo method for evaluating uncertainty and expanded uncertainty 显示文摘 | MAURICE G C BERND R L S | 2006 | Metrologia2006，43，4： | 1 |
| 13 | Crowdsourcing, citizen sensing and sensor Web technologies for public and envi- ronmental health surveillance and crisis management: trends, OGC standards and application examples 显示文摘 | KAkIEL B BERND R DAVID N C | 2011 | International Journal of Health Geographics2011，，10： | 1 |
| 14 | CT angiography of intracranial aneurysms:a focus on post procssing显示文摘 | Bernd F Tomandi Niels C | 2004 | Radio Gaphics2004，24，3： | 1 |
| 15 | Three-dimensional structure of the Stat3 homodimer bound to DNA 显示文摘 | Beeker S Bernd G Muller C | 1998 | Nature1998，394，： | 1 |
| 16 | Targeting phosphoinositide 3- kinase-Moving towards therapy显示文摘 | Romina M Vladimir C Bernd G | 2008 | Biochimiea et Biophysiea Acta2008，1784，： | 1 |
| 17 | Thermal spray processing of nanoscale materials extended abstracts显示文摘 | BERND T C | | Therm Spray Technol0，7，3： | 1 |
| 18 | Skinner and Janith Taylor,Impact and management of purple loosestrife(Lythrum salicaria) in NorthAmerica显示文摘 | Bernd Blossey Luke C | 2001 | Biodiversity and Conservation2001，，10： | 1 |
| 19 | MYB transcription factors in Arabidopsis显示文摘 | Christian Dubos Ralf Stracke Erich Grotewold Bernd Weisshaar Cathie Martin Lo?c Lepiniec | 2010 | Trends in Plant Science2010，，10： | 1 |
| 20 | Evolution of organic matter and ni-trogen during co-composting of olive mill wastewater with solid organicwastes显示文摘 | PAREDES C ROIG A BERND M P | 2000 | Biol Fertil Soils2000，32，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员